Media Center

Taking research sites directly to local communities may hold the key to decreasing patient burden. An estimated 70 percent of potential trial participants live over two hours away from the nearest research center, forcing many to think twice about enrolling in a clinical study.¹ Traveling to distant research sites can be time-consuming, costly and, in some cases, nearly impossible for certain patients due to health concerns, work and childcare responsibilities, and lack of access to transportation.

Care Access CEO and Co-Founder Ahmad Namvargolian is on a mission to remove barriers to clinical trials for sponsors, physicians and patients, and to make research studies accessible for all. This mission was put to the test in the spring of 2020, when the COVID-19 pandemic sent the world screeching to a halt.

(BUSINESS WIRE) — Care Access Research, a decentralized research organization (DRO) that operates as one connected team of physicians and research experts, today announced a collaboration with global biopharmaceutical company AstraZeneca to accelerate a clinical trial in the US for AZD7442, AstraZeneca’s long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19

(BUSINESS WIRE) — Care Access Research, the leader in rapid development and management of high-performing clinical research sites, announced that it is collaborating with global healthcare leader Eli Lilly and Company. Care Access Research is helping Lilly manage the first-of-its-kind system of decentralized, mobile clinical COVID-19 trials as part of the partnership.

BOSTON — (Newswire.com) — Care Access Research, the leader in rapid development and management of high-performing clinical research sites, announced that its validation study of a saliva-based COVID-19 at-home viral test for Phosphorus was granted Emergency Use Authorization by the FDA.